Cost per responder of TNF-α therapies in Germany

Clinical Rheumatology

Volumn 32, Issue 12, 2013, Pages 1805-1809

  Gissel, Christian ^a,b   Repp, Holger ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Cost effectiveness; Etanercept; Germany; Infliximab; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE;

ARTICLE; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; GERMANY; HEALTH INSURANCE; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; TAX;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG COSTS; GERMANY; HUMANS; IMMUNOGLOBULIN G; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; RHEUMATOLOGY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890441193     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2332-1     Document Type: Article

References (24)

1. Scott DL, Wolfe F, Huizinga TWJ (2010) Rheumatoid arthritis. Lancet 376(9746):1094-1108. doi: 10.1016/S0140-6736(10)60826-4
2. Schwabe U, Paffrath D (2012) Arzneiverordnungs-Report 2012. Springer, Berlin
3. Schneider S, Schmitt G, Richter W (2006) Prevalence and correlates of inflammatory arthritis in Germany: data from the First National Health Survey. Rheumatol Int 27(1):29-38
4. Wasmus A, Kindel P, Mattussek S, Raspe HH (1989) Activity and severity of rheumatoid arthritis in Hannover/FRG and in one regional referral center. Scand J Rheumatol Suppl 79:33-44
5. Zink A, Huscher D, Schneider M (2010) How closely does rheumatology treatment follow the guidelines?: ambition and reality. Z Rheumatol 69(4):318-326. doi: 10.1007/s00393-009-0522-7
6. Caro J, Nord E, Siebert U et al (2010) The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ 19(10):1117-1127
7. Krüger K, Wollenhaupt J, Albrecht K et al (2012) German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis: adapted EULAR recommendations and updated treatment algorithm. Z Rheumatol 71(7):592-603. doi: 10.1007/s00393-012-1038-0
8. Gemeinsamer Bundesausschuss (2012) [Rules of Procedure]. BAnz AT 06.09.2012 B5
9. Krüger K (2011) Combination therapy using methotrexate with DMARDs or biologics - current status. Z Rheumatol 70(2):114-122. doi: 10.1007/s00393-010-0684-3
10. Choy EHS, Smith C, Doré CJ, Scott DL (2005) A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 44(11):1414-1421. doi: 10.1093/rheumatology/kei031
11. O'Dell JR, Haire CE, Erikson N et al (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. New Engl J Med 334(20):1287-1291. doi: 10.1056/NEJM199605163342002
12. Hørslev-Petersen K, Hetland ML, Junker P et al (2013) Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis 0:1-8. doi: 10.1136/annrheumdis-2012-202735
13. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF et al (2008) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum-US 58(2 Suppl):S126-S135. doi: 10.1002/art.23364
14. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF et al (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum-US 52(11):3381-3390. doi: 10.1002/art.21405
15. Leirisalo-Repo M, Kautianinen H, Laasonen L et al (2012) Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study. Ann Rheum Dis 0:1-7. doi: 10.1136/annrheumdis-2012-201365
16. van Vollenhoven RF, Ernestam S, Geborek P et al (2009) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 374(9688):459-466. doi: 10.1016/S0140-6736(09)60944-2
17. van Vollenhoven RF, Geborek P, Forslind K et al (2012) Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 379(9827):1712-1720. doi: 10.1016/S0140-6736(12)60027-0
18. O'Dell JR, Petersen K, Leff R et al (2006) Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. J Rheumatol 33(2):213-218
19. Moreland LW, O'Dell JR, Paulus HE et al (2012) A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early, aggressive rheumatoid arthritis. Arthritis Rheum-US. doi: 10.1002/art.34498
20. Liu Y, Wu EQ, Bensimon AG et al (2012) Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther 29(7):620-634. doi: 10.1007/s12325-012-0035-7
21. Smolen JS, Landewé R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964-975. doi: 10.1136/ard.2009.126532
22. Klarenbeek NB, Güler-Yüksel M, van der Kooij SM et al (2011) The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 70(6):1039-1046. doi: 10.1136/ard.2010.141234
23. Detert J, Bastian H, Listing J et al (2012) Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis. doi: 10.1136/annrheumdis-2012-201612
24. Hecken J (2013) [Decision of the Federal Joint Committee on the initiation of benefit assessments for existing pharmaceuticals according to § 35a par. 6 SGB V and Chapter 5 § 16 VerfO]. BAnz AT 07.05.2013 B4